A Look At Quest Diagnostics (DGX) Valuation After Strong Q1 Beat And Raised Full Year Guidance

Quest Diagnostics (DGX) is back in focus after a strong first quarter, with revenue and adjusted earnings per share ahead of expectations, and management lifting full year guidance for both metrics.

See our latest analysis for Quest Diagnostics.

The stock has been firming up recently, with a 7 day share price return of 2.53% and year to date share price return of 12.33%. The 1 year total shareholder return of 14.42% sits on top of three and five year total shareholder returns of 54.80% and 69.14%, suggesting momentum has broadly been building even after a weaker 90 day patch.

If strong diagnostics earnings have your attention, it could be a good moment to widen your watchlist and look for other healthcare testing and AI opportunities using our 34 healthcare AI stocks

With earnings beating expectations, guidance raised, and the stock trading at a discount to analyst targets and some intrinsic value estimates, you have to ask yourself: Is Quest Diagnostics still undervalued or already pricing in future growth?

Most Popular Narrative: 13% Undervalued

Quest Diagnostics' most followed narrative points to a fair value of $223.25 per share, compared with the last close at $195.21, implying upside based on analysts' long term assumptions and a 7.11% discount rate.

The rising importance of health data analytics and Quest's role as a "lab engine" for consumer wellness brands positions the company to benefit from new revenue streams and further monetization opportunities as healthcare becomes more data-driven, supporting long-term earnings power.

Read the complete narrative.

Curious what underpins that fair value gap? The narrative leans heavily on steady top line expansion, firmer margins, and a future earnings multiple that assumes investors still pay up for consistent cash generation.

Result: Fair Value of $223.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, analyst optimism still hinges on reimbursement policy and payer mix, where PAMA cuts or greater exposure to government payers could pressure Quest’s pricing power and margins.

Find out about the key risks to this Quest Diagnostics narrative.

Next Steps

If this sounds mixed to you, that is the point. Use the full set of data quickly and weigh up its 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you may miss out on stronger income, value, and quality opportunities that better fit your goals and risk comfort.

• Target reliable cash flow by using the 10 dividend fortresses to spot income ideas that might suit a long term portfolio.
• Hunt for potential bargains through the 48 high quality undervalued stocks and see which stocks the data suggests could be priced below their fundamentals.
• Protect your downside by scanning the 65 resilient stocks with low risk scores and focus on companies that score well on overall resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com